Objective: To determine the 1 H MR spectroscopic (MRS) findings and intergroup differences among common dementias: Alzheimer disease (AD), vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD). Methods: The authors consecutively recruited 206 normal elderly subjects and 121 patients with AD, 41 with FTLD, 20 with DLB, and 8 with VaD. The 1 H MRS metabolite ratio changes in common dementias were evaluated with respect to normal and also differences among the common dementias. Results: N-Acetylaspartate (NAA)/ creatine (Cr) was lower than normal in patients with AD, FTLD, and VaD. Myo-inositol (mI)/Cr was higher than normal in patients with AD and FTLD. Choline (Cho)/Cr was higher than normal in patients with AD, FTLD, and DLB. There were no metabolite differences between patients with AD and FTLD or between patients with DLB and VaD. NAA/Cr was lower in patients with AD and FTLD than DLB. MI/Cr was higher in patients with AD and FTLD than VaD. MI/Cr was also higher in patients with FTLD than DLB. Conclusions: NAA/Cr levels are decreased in dementias that are characterized by neuron loss, such as AD, FTLD, and VaD. MI/Cr levels are elevated in dementias that are pathologically characterized by gliosis, such as AD and FTLD. Cho/Cr levels are elevated in dementias that are characterized by a profound cholinergic deficit, such as AD and DLB.
NEUROLOGY 2004;63: [1393] [1394] [1395] [1396] [1397] [1398] Alzheimer disease (AD) is the most common cause of dementia. Dementing illnesses that are less common, but may enter into the clinical differential diagnosis, are vascular dementia (VaD), dementia with Lewy bodies (DLB), and frontotemporal lobar degeneration (FTLD). 1,2 1 H MR spectroscopy ( 1 H MRS) is unique among diagnostic imaging modalities because the signals from several different metabolites are measured within a single measurement period. Each metabolite in turn is sensitive to a different aspect of in vivo pathologic processes at the molecular or cellular level. In principle, it may be possible to generate a disease-specific spectroscopic profile with multiple contributing components. The metabolite Nacetylaspartate (NAA) is consistently found to be lower and the metabolite myo-inositol (mI) higher in 1 H MRS studies of patients with AD than cognitively normal elderly subjects. [3] [4] [5] [6] [7] [8] There are conflicting reports about choline (Cho) levels in AD. Some studies identified elevated Cho levels in people with AD, and some did not. 9 NAA levels are reduced in patients with VaD, and white matter NAA is lower in patients with VaD than in patients with AD. [10] [11] [12] Gray matter mI/Cr levels, on the other hand, are normal in patients with VaD. 13 1 H MRS metabolite changes in FTLD are similar to AD, with lower NAA/Cr and higher mI/Cr levels than normal. 14, 15 1 H MRS studies in common dementias are limited to comparing the 1 H MRS findings in AD with those in other dementias, 14 FTLD, 15 and VaD. [11] [12] [13] 16 We are not aware of any study that has compared the 1 H MRS metabolite profiles among the most common dementias. The objectives of this study were to identify the 1 H MRS metabolite changes in each of the common dementias with respect to normal and to identify 1 H MRS metabolite differences among the common dementias.
Methods. Recruitment of subjects. All subjects of this project were recruited through the Alzheimer's Disease Research Center (ADRC) and Alzheimer's Disease Patient Registry (ADPR) at the Mayo Clinic, Rochester, MN, 17 as part of an ongoing institutional review board-approved MRI/ 1 H MRS project. All individuals participating in the ADRC/ADPR are evaluated by a behavioral neurologist and a neuropsychologist. They undergo neurologic examination, neuropsychological testing, and basic laboratory testing. At the completion of the evaluation, a consensus committee meeting is held involving the behavioral neurologists, neuropsychologists, nurses, and the geriatrician who evaluate the subjects. All of the subjects undergo structural brain MRI. Subjects with structural abnormalities other than vascular disease that could produce dementia, such as tumors and subdural hematoma, as well as those who had concurrent illnesses or treatments Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the October 26 issue to find the title link for this article. interfering with cognitive function other than AD, VaD, DLB, and FTLD were excluded from this study. We studied only patients older than 40 years.
A diagnosis of dementia was based on Diagnostic and Statistical Manual of Mental Disorders (3rd rev. ed) criteria. 18 The clinical diagnoses of AD, VaD, DLB, and FTLD were made using published consensus criteria. 19 Only patients meeting the criteria for one of the dementias (AD, VaD, DLB, and FTLD) were included in this study. Patients who met the criteria for two or more of the different dementias were excluded.
Normal subjects were individuals who 1) were independently functioning community dwellers, 2) did not have active neurologic or psychiatric conditions, 3) had no cognitive complaints, 4) had a normal neurologic exam, and 5) were not taking any psychoactive medications in doses that would impact cognition.
Single-voxel 1 H MRS. 1 H MRS studies were performed with the LX system automated single-voxel 1 H MRS package (PROBE/ SV; GE Medical Systems, Milwaukee, WI). 20 An 8-cm 3 (2 ϫ 2 ϫ 2-cm) voxel was placed on a midsagittal T1-weighted image covering right and left posterior cingulate gyri and inferior precunei (figure 1). Point-resolved spectroscopy (PRESS) pulse sequence with repetition time of 2,000 milliseconds, echo time of 30 milliseconds, 2,048 data points, and 128 excitations was used for the examinations. The prescan algorithm of PROBE automatically adjusts the transmitter and receiver gains and center frequency. The local magnetic field homogeneity is optimized with the three-plane auto-shim procedure, and the flip angle of the third water suppression pulse is adjusted for chemical shift water suppression (CHESS) prior to PRESS acquisition. The single-voxel 1 H MRS scan time is about 6 minutes. Metabolite intensity ratios are automatically calculated at the end of each PROBE/SV acquisition. 1 H MRS variables that were analyzed for this study were NAA/Cr, Cho/Cr, and mI/Cr ratios.
Statistical analysis. Gender differences among the clinical groups (normal, AD, FTLD, DLB, and VaD) were tested with the 2 test. Analysis of variance (ANOVA) was used to compare clinical groups with respect to age, Clinical Dementia Rating (CDR), Dementia Rating Scale (DRS), Mini-Mental State Examination (MMSE), and the three metabolite ratios. To control the experiment-wise error rate, we first tested for differences in each metabolite ratio among the five groups (i.e., including normal subjects) using a one-way ANOVA. If the test was significant at the 0.05 level, we tested which groups differed from normal subjects using the Dunnett test. We then performed a one-way ANOVA excluding the normal subjects. If this dementia-group ANOVA was significant at the 0.05 level, we used the Fisher least significant difference procedure to make pair-wise comparisons of metabolite ratios among the groups. All tests were two sided. The effects of age on metabolite ratios were tested by linear regression analysis, and the gender effects were tested with Student t-tests in normal subjects only, as the data in normal subjects should be free of the confounding effects of disease.
Results. Demographic aspects. We consecutively recruited 206 cognitively normal elderly volunteers, 121 patients with AD, 41 patients with FTLD, 20 patients with DLB, and 8 patients with VaD from October 2001 until January 2003. We excluded 36 patients from this study who fulfilled the diagnostic criteria for more than one dementia because they constitute a clinically and pathologically heterogeneous group and there are no accepted research criteria available to classify the different mixed dementia subtypes. Demographic aspects of the study groups are listed in table 1. There were no gender differences between the clinical groups ( 2 , p ϭ 0.06). Mean ages of clinical groups were different (ANOVA, p Ͻ 0.0001). Patients with VaD were older than patients with DLB (p ϭ 0.04). Patients with FTLD were younger than those of all other clinical groups (normal, AD, VaD, DLB) (p Ͻ 0.01 for all comparisons). We did not find any association between age and metabolite ratios in the normal subjects, probably due to the older age range of our normal subject group (see the supplementary material on the Neurology Web site; go to www.neurology.org). Because there was no association between age or gender (p Ͼ 0.05) and metabolite ratios in normal subjects, metabolite measurements were not adjusted for age or gender in normal subjects or patients. The DRS and MMSE scores of patients with different dementias were lower than those of the normal subjects (p Ͻ 0.0001 for all comparisons). There were no differences between the CDR, DRS, and MMSE scores of patients with different dementias on ANOVA, indicating that clinical dementia severity was similar between the dementia groups. Ninety-one of 121 patients with AD, 16 of 41 patients with FTLD, and 17 of 20 patients with DLB were being treated with cholinesterase inhibitors.
All patients with vascular dementia had leukoariosis on MRI. In addition, four had cortical and four had subcortical infarctions. None of the lesions involved the posterior cingulate gyri or inferior precunei. The 1 H MRS voxel included only the normal-appearing brain tissue on MRI in all subjects.
1 H MRS differences between subjects with different dementias and normal elderly subjects. The 1 H MRS metabolite differences from normal in patients with AD, FTLD, DLB, and VaD are listed in table 2. NAA/Cr ratios were lower than normal in patients with AD (p Ͻ 0.001), VaD (p ϭ 0.08), and FTLD (p Ͻ 0.001) but not different from normal in patients with DLB. Cho/Cr ratios were higher than normal in patients with AD (p ϭ 0.05), DLB (p ϭ 0.001), and FTLD (p ϭ 0.02) but not different from normal in patients with VaD. MI/Cr ratios were higher than normal in patients with AD and FTLD (p Ͻ 0.001 for both comparisons) but not different from normal in patients with DLB and VaD. Examples of 1 H MRS from each of the clinical groups are shown in figure 2.
1 H MRS differences between the dementia groups. The 1 H MRS metabolite ratios NAA/Cr (p ϭ 0.009) and mI/Cr (p ϭ 0.008) were different between the dementia groups on ANOVA. Cho/Cr was not different between dementia groups. 1 H MRS metabolites that differed between dementias are summarized in table 3. NAA/Cr was higher in patients with DLB than AD and FTLD (p Ͻ 0.01 for both comparisons). MI/Cr was higher in patients with AD than VaD (p ϭ 0.02) and higher in patients with FTLD than DLB (p ϭ 0.02) and VaD (p ϭ 0.003). There were no differences between patients with AD and FTLD or between VaD and DLB.
Discussion. The objective of this study was to identify 1 H MRS metabolite signatures of common dementias to determine if 1 H MRS might be useful in differentiating them. Whereas the literature on neuroimaging findings in people with AD is extensive, the neuroimaging literature on other common dementias is limited. Cross-sectional studies like this one are required as the first step toward identifying neuroimaging markers that might be useful biomarkers for dementing disorders.
Our data indicate that posterior cingulate NAA/Cr levels were decreased in all dementias studied except in patients with DLB. Normal NAA/Cr levels were previously reported in this region in patients with DLB. 21 NAA is a neuronal metabolite, and NAA levels correlate with neuronal and axonal density. 22, 23 Decreased NAA levels normalize with the recovery of cognitive performance after head trauma 24 or termination of seizures after epilepsy surgery 25 ; therefore, NAA is also regarded as a marker for neuronal function. Patients with DLB have preserved neuronal numbers at autopsy 26 and have normal limbic cortical volumes on voxel-based morphometry, which distinguishes them from patients with AD. 27 The normal NAA/Cr levels observed in our study suggest integrity of neurons in the posterior cingulate gyrus of patients with DLB and are consistent with other studies in this respect.
Patients with VaD had a trend toward lower NAA/Cr levels than normal. All of the patients with 28 This effect, if present in our data, would only decrease the NAA/Cr differences between AD, FTLD, and normal subjects. This effect would have negligible impact on our data concerning differentiating the AD and DLB from each other, because most of the patients with AD and DLB were taking cholinesterase inhibitors. However, it is possible that the NAA/Cr differences between AD and FTLD were obscured because the proportion of AD subjects taking cholinesterase inhibitors was greater than FTLD subjects.
Cho/Cr ratios were elevated in patients with degenerative dementias compared with normal subjects but not in patients with VaD. Normal Cho/Cr levels in the cortical gray matter of patients with VaD are in agreement with previous studies. [11] [12] [13] The largest amount of Cho in the brain is in the Chobound membrane phospholipids. Among the cytosolic Cho-containing species, free Cho and acetylcholine are very low in abundance in brain tissue. The Cho peak in the 1 H MRS spectra of the brain is thought to be composed of cytosolic glycerophosphocholine and phosphocholine, which are the products of membrane phosphatidylcholine breakdown and precur- (AD) (B) , a patient with frontotemporal lobar degeneration (FTLD) (C), a patient with dementia with Lewy bodies (DLB) (D), and a patient with vascular dementia (VaD) (E). The N-acetylaspartate (NAA)/creatine (Cr) ratio is lower in patients with AD, FTLD, and VaD than both the DLB and the normal subjects. The choline (Cho)/Cr ratio is higher in patients with AD, FTLD, and DLB than the normal subject. The myo-inositol (mI)/Cr ratio is higher in the patients with AD and FTLD than both the VaD and the normal subjects. All spectra are scaled to the height of the reference peak Cr, which is held constant across (A) through (E). sors of Cho and acetylcholine synthesis. 29 One possible explanation for the elevation of Cho in AD and FTLD is increased membrane turnover due to dying back of the neuropil. It has also been postulated that the elevation of the Cho peak is the consequence of membrane phosphatidylcholine catabolism to provide free Cho for the chronically deficient acetylcholine production in AD. 11, 30 The only measurement that was different from normal in patients with DLB was the Cho/Cr ratio. The activity of choline acetyltransferase, the enzyme responsible for acetylcholine synthesis from free Cho, is reduced earlier and more severely in the disease course of DLB than AD. 31 Furthermore, patients with DLB who were treated with cholinesterase inhibitors have shown substantial cognitive improvement, 32 revealing the functional significance of acetylcholine deficiency in DLB. Although the basis for the elevation of Cho/Cr in AD and DLB is not completely understood, down-regulation of choline acetyltransferase activity may be responsible for this change in both pathologic processes. The fact that Cho/Cr levels decrease with cholinergic agonist treatment in AD 33 raises the possibility that Cho/Cr levels could be a biomarker of therapeutic efficacy in AD and DLB drug trials. This would, however, require further validation with longitudinal studies.
MI/Cr levels were elevated in patients with AD and FTLD and were not different from normal in patients with DLB and VaD. MI is primarily isolated from glial cells. 34 MI levels correlate with glial proliferation in inflammatory CNS demyelination. 23 Our findings of elevated mI levels in AD and FTLD are in agreement with others 4, 6, 8, 15 and support the hypothesis that mI may be a marker for glial cell activity in these neurodegenerative diseases. As there is no evidence that glial proliferation is a characteristic of DLB pathology, normal mI/Cr levels would be expected in DLB. Our observation of normal posterior cingulate mI/Cr in patients with VaD is not surprising because the portion of the brain with vascular pathology evident on structural MRI was not included in the 1 H MRS voxel. Our data do not address whether 1 H MRS acquired directly from the ischemic brain areas would reveal elevated mI/Cr levels.
The metabolite measurements in this study were obtained from a single region in the brain: right and left hemispheric posterior cingulate gyri and inferior precunei. It would seem intuitive at first that 1 H MRS imaging, in which 1 H MRS data are simultaneously acquired from multiple voxels, would be a more appropriate way to comprehensively study different dementias. We chose to use single-voxel 1 H MRS for several technical reasons related to data quality. Achieving uniform water suppression across the entire volume and removal of signal contributions from subcutaneous lipids are difficult with short echo time 1 H MRS imaging. 35, 36 Using short echo time (30 milliseconds) in 1 H MRS acquisitions was critical to this study, because mI has a relatively short transverse relaxation time and can be quanti-fied only at short echo times. The single-voxel 1 H MRS acquisition in this study was included as part of a comprehensive longitudinal MR protocol. Because of time constraints, we were able to perform only one single-voxel 1 H MRS acquisition per exam. Although acquiring single-voxel data from several locations in the brain would have been useful, such an approach would require an excessively long acquisition protocol that could produce unwanted subject attrition from the longitudinal study. We acknowledge that single-voxel 1 H MRS measurements from other regions in the brain could have improved differentiating among the dementias, and we might have observed intergroup differences of greater magnitude had we sampled different regions. Furthermore, while many reports have shown Cr to be stable in AD, 9 it is not known if this holds true for other dementias. It is possible that absolute quantitation of metabolite concentrations 37 may differentiate the clinical groups better than ratios.
Overall, our in vivo 1 H MRS data are consistent with the biochemical changes that would be expected based on the known pathology in each of the dementias studied. However, we used clinical diagnoses for dementia classification. Correlations with neuropathology would more firmly validate the biologic significance of 1 H MRS changes in common dementias. Our data indicate that 1 H MRS metabolite profiles may be useful biochemical imaging markers in common dementias. This, however, needs to be tested with longitudinal studies and in therapeutic trials.
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